Podoplanin: an emerging cancer biomarker and therapeutic target

Harini Krishnan; Julie Rayes; Tomoyuki Miyashita; Genichiro Ishii; Edward P. Retzbach; Stephanie A. Sheehan; Ai Takemoto; Yao Wen Chang; Kazue Yoneda; Jun Asai; Lasse Jensen; Lushun Chalise; Atsushi Natsume; Gary S. Goldberg

doi:10.1111/cas.13580

Podoplanin: an emerging cancer biomarker and therapeutic target

Harini Krishnan, Julie Rayes, Tomoyuki Miyashita, Genichiro Ishii, Edward P. Retzbach, Stephanie A. Sheehan, Ai Takemoto, Yao Wen Chang, Kazue Yoneda, Jun Asai, Lasse Jensen, Lushun Chalise, Atsushi Natsume^*, Gary S. Goldberg

^*Corresponding author for this work

Cardiovascular Sciences

Research output: Contribution to journal › Review article › peer-review

52 Citations (Scopus)

118 Downloads (Pure)

Abstract

Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

Original language	English
Pages (from-to)	1292-1299
Number of pages	8
Journal	Cancer Science
Volume	109
Issue number	5
Early online date	25 Mar 2018
DOIs	https://doi.org/10.1111/cas.13580
Publication status	Published - May 2018

Keywords

c-type lectin-like receptor 2
cancer
chemotherapy
podoplanin

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/cas.13580Licence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Krishnan_et_al_Podoplanin_An_emerging_cancer_biomarker_and_therapeutic_target_Cancer_Science_2018Final published version, 519 KBLicence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

https://onlinelibrary.wiley.com/doi/full/10.1111/cas.13580Licence: Creative Commons: Attribution-NonCommercial (CC BY-NC)

Cite this

@article{32b2ea2265df44379ab923c5ea327459,

title = "Podoplanin: an emerging cancer biomarker and therapeutic target",

abstract = "Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.",

keywords = "c-type lectin-like receptor 2, cancer, chemotherapy, podoplanin",

author = "Harini Krishnan and Julie Rayes and Tomoyuki Miyashita and Genichiro Ishii and Retzbach, {Edward P.} and Sheehan, {Stephanie A.} and Ai Takemoto and Chang, {Yao Wen} and Kazue Yoneda and Jun Asai and Lasse Jensen and Lushun Chalise and Atsushi Natsume and Goldberg, {Gary S.}",

year = "2018",

month = may,

doi = "10.1111/cas.13580",

language = "English",

volume = "109",

pages = "1292--1299",

journal = "Cancer Science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Podoplanin

T2 - an emerging cancer biomarker and therapeutic target

AU - Krishnan, Harini

AU - Rayes, Julie

AU - Miyashita, Tomoyuki

AU - Ishii, Genichiro

AU - Retzbach, Edward P.

AU - Sheehan, Stephanie A.

AU - Takemoto, Ai

AU - Chang, Yao Wen

AU - Yoneda, Kazue

AU - Asai, Jun

AU - Jensen, Lasse

AU - Chalise, Lushun

AU - Natsume, Atsushi

AU - Goldberg, Gary S.

PY - 2018/5

Y1 - 2018/5

N2 - Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

AB - Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

KW - c-type lectin-like receptor 2

KW - cancer

KW - chemotherapy

KW - podoplanin

UR - http://www.scopus.com/inward/record.url?scp=85047848192&partnerID=8YFLogxK

U2 - 10.1111/cas.13580

DO - 10.1111/cas.13580

M3 - Review article

C2 - 29575529

AN - SCOPUS:85047848192

SN - 1347-9032

VL - 109

SP - 1292

EP - 1299

JO - Cancer Science

JF - Cancer Science

IS - 5

ER -

Podoplanin: an emerging cancer biomarker and therapeutic target

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this